Phase I trial of weekly nab-paclitaxel plus cyclophosphamide for metastatic breast cancer

INTERVENTION: Cyclophosphamide:600 mg / m2, day1 nab‐paclitaxel:80‐150 mg / m2, day1,8,15 every 3 weeks CONDITION: advanced or metastatic breast cancer PRIMARY OUTCOME: To determine maximum tolerated dose and recommended dose INCLUSION CRITERIA: 1)Histrogical confirmed inoperable and metastatic breast cancer 2)HER2 negative confirmed by IHC or FISH 3)At least one measurable lesion 4)Performance status of 0 or 1 5)Age are 20‐75 years old 6)Required baseline laboratory date within 14 days WBC>=4000/mm3 Neu>=2000/mm3 Hb>=9.0g/dL Plt>=100000/mm3 T‐Bill=<1.5mg/dL AST<=100IU/L ALT<=100IU/L Cr<=1.2mg/dL 7)Written informed consent